Novel Anti-VEGF Drug Effective in Kidney Cancer - MedPage Today

Results from a head-to-head phase III trial comparing the new drug, tivozanib, with sorafenib (Nexavar) in 517 patients showed significantly longer progression-free survival (11.9 months versus 9.1 months, P=0.042), according to Robert J.

Scientists may be step closer to developing new therapy for AML - News-Medical.Net

Scientists at Virginia Commonwealth University Massey Cancer Center may be one step closer to developing a new therapy for acute myeloid leukemia (AML) after discovering that the targeted agents obatoclax and sorafenib kill leukemia cells much ...

Phase 3 Study Update of Tivozanib for First-Line Advanced Renal Cell Carcinoma - Monthly Prescribing Reference

AVEO and Astellas announced detailed data from TIVO-1 (Tivozanib Versus Sorafenib in 1 st line Advanced Renal Cell Carcionma [RCC]). TIVO-1 was a global, randomized Phase 3 superiority clinical trial evaluating the efficacy and safety of investigational ...

Sorafenib targets acute myeloid leukemia driven by mutant FLT3 gene - Xagena Medical News

A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with acute myeloid leukemia ( AML ), the most common and lethal form of adult leukemia, researchers at The University of Texas M. D. Anderson Cancer ...

Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival - Yahoo Finance

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., May 22, 2012 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (ONXX) today announced that a Phase 3 trial evaluating Nexavar ® (sorafenib) tablets in patients with ...

A Few Thoughts On The actual Near Future For Doxorubicin - 1UP.COM

TKI to the other, either with sorafenib followed by sunitinib SoSu or sunitinib followed by sorafenib SuSo. Everolimus was associatedwith a median PFS of . months in the in general inhabitants versus . months for placebo hazard ratio HR . self confidence ...

Aveo, Astellas Report Positive Data from Phase III Comparative Tivozanib Trial in RCC - Genetic Engineering News

Aveo Oncology and partner Astellas Pharma Europe reported positive data from the pivotal Phase III study Viro-1, comparing the once-daily oral tyrosine kinase inhibitor candidate tivozanib with sorafenib in 517 patients with advanced renal cell ...

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Yahoo Finance

AVEO Oncology (NASDAQ:AVEO - News) and Astellas Pharma Inc. (TSE:4503) today announced that detailed data from TIVO-1 (Tivozanib Versus Sorafenib in 1 st line Advanced RCC), will be presented on June 2 in an oral session by the principal ...

Pfizer does not meet primary endpoint in TORISEL Phase 3 study for advanced RCC - News-Medical.Net

Overall survival, a secondary endpoint in the study, showed statistical significance favoring patients randomized to the sorafenib arm. Adverse events in this study were consistent with the known safety profiles for both drugs. Full efficacy and ...

Pfizer Provides Topline Results From Phase 3 Study Of Torisel As Second-Line Treatment - The FINANCIAL

Overall survival, a secondary endpoint in the study, showed statistical significance favoring patients randomized to the sorafenib arm. Adverse events in this study were consistent with the known safety profiles for both drugs. Full efficacy and safety ...